Samsung Bioepis, a company that makes copies of biologic medicines (called biosimilars), has signed a new global deal with Sandoz, another pharmaceutical company. Together, they will work on developing and selling up to five new biosimilar medicines. This agreement continues a partnership that has grown stronger over the past few years. The deal was announced in Incheon, Korea, but it does not include China, Hong Kong, Taiwan, Macau, or South Korea. The companies have not shared other details about the agreement. Under this deal, Samsung Bioepis will handle the development, regulatory approvals in key markets, and manufacturing of the medicines. Sandoz will be responsible for selling the medicines in the areas covered by the agreement. Kyung-Ah Kim, the CEO of Samsung Bioepis, said, ‘We are excited to expand our successful partnership with Sandoz and secure agreements to develop multiple biosimilar medicines that are still in the early stages of research. This agreement is a big step forward in making sure patients with serious conditions, who have limited access to life-changing medicines, can get the treatments they need.’ She also added, ‘At Samsung Bioepis, we remain committed to improving access to biosimilar medicines by strengthening our product pipeline and making these medicines available to patients and healthcare systems worldwide.’ One of the medicines mentioned in the agreement is SB36, which is currently being tested in the lab and will be similar to Entyvio (vedolizumab). Entyvio is used to treat adults with Crohn’s disease, ulcerative colitis, and pouchitis. This new agreement builds on previous collaborations between the two companies. For example, they partnered to develop PYZCHIVA (ustekinumab), which was launched in Europe in July 2024 and in the United States in February 2025. In December 2025, they also signed a deal to sell EPYSQLI, a biosimilar to Soliris (eculizumab), in the Middle East and Africa. This new partnership shows Samsung Bioepis’ ongoing effort to expand its range of biosimilar medicines, focusing on treatments for immune system and cancer-related conditions. Their goal is to make advanced therapies more accessible to patients around the world.